A Phase 1, Randomized Investigator-And-Subject-Blind, Sponsor Open, Placebo Controlled Two-Part Study To Characterize The Pharmacokinetics And Pharmacodynamics Of Single Doses Of Pf-05297909 In Healthy Adult Subjects.

Trial Profile

A Phase 1, Randomized Investigator-And-Subject-Blind, Sponsor Open, Placebo Controlled Two-Part Study To Characterize The Pharmacokinetics And Pharmacodynamics Of Single Doses Of Pf-05297909 In Healthy Adult Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2012

At a glance

  • Drugs PF 5297909 (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Most Recent Events

    • 12 Mar 2012 Actual patient number 51 added as reported by ClinicalTrials.gov.
    • 12 Mar 2012 Actual end date Feb 2012 added as reported by ClinicalTrials.gov.
    • 12 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top